ASX 200
Checkout Our Recommendations for free - 7 day free trial Subscribe Now

Cambium Bio Limited - CMB share price

Current Price: $ - -
Updated At: -

About

Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Its technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Elate Ocular is formulated from the processing of base human platelets sourced not from patients, but generally healthier younger eligible donors at U.S. blood collection centers. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It also manufactures and sells stem cell growth supplements, such as UltraGRO Advanced, UltraGRO Pure (xeno-free), and UltraGRO Pure GI (xeno-free, gamma irradiated).

Company Profile

Market Cap: -
Enterprise Value: -
Shares Outstanding: -
Shares Float: -
P/E Ratio: -
PEG Ratio: -
Book Value: -
Revenue TTM: -
Div Yield: -
Earning Share: -
Dividend per Share: -
Profit Margin: -

Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.

Top Shareholders

Price Summary

Today's High -
Price High
Today's Low -
Price Low
52 Week High: -
Price High
52 Week Low: -
Price Low
Price High
Week's High: -
Price Low
Week's Low: -

Price Chart

Get Your FREE Report

Discover the Top ASX Stocks to Invest In 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...